SanBio (OTCMKTS:SNBIF) Stock Falls 74.6% – Should You Sell?

SanBio Company Limited (OTCMKTS:SNBIF – Get Free Report)’s stock price traded down 74.6% during mid-day trading on Wednesday. The stock traded as low as C$5.51 and last traded at C$5.85. 18,762 shares changed hands during trading, an increase of 2,756% from the average session volume of 657 shares. The stock had previously closed at C$23.00.

SanBio Trading Down 74.6%

The business’s 50 day simple moving average is C$10.02 and its 200 day simple moving average is C$10.08.

SanBio Company Profile

(Get Free Report)

SanBio Co, Ltd. is a Japan-based biotechnology company focused on developing regenerative cell therapies for disorders of the central nervous system. The company’s research is aimed at repairing or restoring neurological function in patients with conditions that have limited treatment options, including chronic traumatic brain injury and stroke.

SanBio’s lead investigational product, SB623, is a cell-based therapy derived from allogeneic bone marrow mesenchymal stem cells. In Japan, the product received conditional and time-limited approval under the name AKUUGO Injection for the treatment of chronic motor dysfunction caused by traumatic brain injury.

Featured Stories

Receive News & Ratings for SanBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SanBio and related companies with MarketBeat.com's FREE daily email newsletter.